...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Relationship between pretreatment specific IgE and the response to omalizumab therapy.
【24h】

Relationship between pretreatment specific IgE and the response to omalizumab therapy.

机译：预处理前的特异性IgE与奥马珠单抗治疗反应之间的关系。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Omalizumab, an anti-IgE antibody, has proven efficacy in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. While previous analyses have had some limited success in predicting which patients will gain greatest benefit based on pretreatment baseline characteristics, it remains important to try to improve this predictability. METHODS: Following a run-in phase, patients (12-75 years) inadequately controlled despite current therapy were randomized to receive omalizumab or placebo for 28 weeks in a double-blind, parallel-group, multicenter study (INNOVATE). Univariate analyses were performed to assess whether pretreatment specific IgE serum levels and related variables could be identified that were predictive of a response to omalizumab patients (n = 337) enrolled in INNOVATE. Response was measured via variables including exacerbations, QoL, FEV(1) and physicians' overall assessment. RESULTS: A total of 305 patients (90.5%) were sensitive to more than one allergen and the majority of patients were positive to D1 Dermatophagoides pteronyssinus and D2 Dermatophagoides farinae. Patients with relatively high values of D1 or D2, but with these making a relatively low contribution to total specific IgE load, appeared to attain most benefit from omalizumab. However, no consistent predictive effect for omalizumab response was observed either for total specific IgE or levels of IgEs specific for individual allergens. CONCLUSIONS: Based on these data, pretreatment allergen-specific IgE levels do not provide any better prediction of response to treatment as compared with pretreatment total IgE. At present, the most reliable method of identifying patients who respond to omalizumab treatment remains a physician's assessment.
机译：背景：Omalizumab是一种抗IgE抗体，已证明对中重度和重度持续性过敏性（IgE介导）哮喘患者有效。尽管先前的分析在根据治疗前的基线特征预测哪些患者将获得最大收益方面取得了有限的成功，但尝试改善这种可预测性仍然很重要。方法：在进入磨合期后，在双盲，平行组，多中心研究（INNOVATE）中，尽管进行了当前治疗，但仍未得到充分控制的患者（12-75岁）被随机接受奥马珠单抗或安慰剂治疗28周。进行单因素分析以评估是否可以确定治疗前特定的IgE血清水平和相关变量，这些变量可预测对参加INNOVATE的奥马珠单抗患者（n = 337）的反应。通过变量加重，包括QoL，FEV（1）和医生的总体评估来衡量反应。结果：共有305例患者（占90.5％）对一种以上的过敏原敏感，大多数患者对D1蝶粉金刚菌和D2粉蝶Dermatophagoides呈阳性。 D1或D2值相对较高但对总特异性IgE负荷贡献相对较低的患者似乎从奥马珠单抗中获益最大。但是，无论是总特异性IgE还是个别变应原特异性IgE的水平，均未观察到奥马珠单抗反应的一致预测效果。结论：基于这些数据，与治疗前总IgE相比，治疗前变应原特异性IgE水平不能提供对治疗反应的任何更好的预测。目前，鉴定对奥马珠单抗治疗有反应的患者的最可靠方法仍然是医生的评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号